Project Name: High Risk Acute Coronary Syndrome (ACS) Secondary prevention Clinic – Newcastle Upon Tyne Hospitals NHS Foundation Trust

Project Summary:

The CWP is structured such that a Band 8A Clinical Pharmacist will provide tailored care for patients, to improve patients' outcomes by optimising medications following an acute coronary syndrome (ACS).

The aim of this project is to deliver an in house secondary care service to improve delivery of NICE approved innovative therapies to optimise secondary prevention and reduce risk of ischaemic events in high-risk ACS patients by utilising the approved NICE therapies and following the NEELI Guidance.   

Objectives of the CWP are :-

  • Optimise lipid management among patients with hypercholesterolaemia who are statin intolerant or despite statin therapy are not meeting NICE/NEELI defined low non-HDL targets 
  • Assess and offer novel cholesterol lowering medicines to patients eligible in line with NICE  and NEELI guidance 
  • Provide patient tailored support and education to promote adherence with treatment and optimisation of non-HDL levels. 
  • Reduce readmissions of high risk ACS patients  

Expected Benefits:

Patient Benefits

  • Improved access to lipid management care leading to optimal diagnosis and management of ASCVD treatments.  
  • Enhanced experience around ASCVD with ongoing management of the condition.  
  • Improved access to appropriate medication for suitable patients to preserve health and prevent long-term events  or mortality.
  • Easier access to lipid management and specialist clinic.

NHS Benefits

  • Increased proportion of ASCVD patients receiving expert  care in speciality clinic.Reduction in ASCVD referral rates to secondary care post discharge
  • Increased proportion of patients receiving guideline-directed pharmacotherapy 
  • Provide patient tailored support and education to promote adherence with treatment and optimisation of non-HDL levels.

Novartis Benefits

  • Insight on the appropriate use of ASCVD licensed medicines in line with NICE guidelines, including Novartis’s medicine 
  • Enhanced reputation, and supporting Novartis’ vision that no patient should have to wait for an extraordinary life, by supporting high quality Collaborative Working with healthcare organisations which addresses the problem of health inequalities  
  • Ethical, professional, and transparent relationship between Novartis and the Healthcare Organisation

Start Date & Duration: January 2023– 30 months with 24 months clinical activity